ArticleAmerican journal of cardiovascular disease2026
Relationship between the triglyceride-glucose index and non-alcoholic fatty liver disease among individuals with atrial fibrillation.
Article in American journal of cardiovascular disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe triglyceride-glucose (TyG) index serves as a reliable surrogate marker of insulin resistance. Accumulating evidence links an elevated TyG index to increased cardiovascular risk, but its relationship with nonalcoholic fatty liver disease (NAFLD) in atrial fibrillation (AF) patients remains underexplored. This study aimed to investigate the association between the TyG index and NAFLD incidence among AF patients.
methodsWe conducted a retrospective analysis of 298 AF patients from a single tertiary care center. NAFLD was diagnosed via hepatic ultrasonography after secondary causes were excluded. TyG index was calculated as ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2]. Logistic regression models were employed to assess the independent association between the TyG index and NAFLD.
resultsThe NAFLD prevalence was 27.9% (83/298). Patients with NAFLD presented significantly greater TyG index values (8.90 ± 0.05 vs. 8.62 ± 0.04; P < 0.001). After multivariable adjustment, each 1-unit increment in the TyG index independently predicted NAFLD (OR 2.194, 95% CI 1.149-4.190; P = 0.017). Receiver operating characteristic curve analysis demonstrated moderate discriminative ability (AUC 0.667, 95% CI 0.601-0.732). A dose-response relationship was observed (P for trend < 0.001), with NAFLD incidence increasing progressively across TyG tertiles (12.87%, 29.81%, and 40.82%).
conclusionsAn elevated TyG index is an independent risk factor for NAFLD in AF patients, suggesting a shared metabolic pathophysiology between insulin resistance, hepatic steatosis, and cardiac arrhythmia. The TyG index may serve as a readily available tool for NAFLD risk stratification in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.